ASX Announcement

Medibio Limited – 1/22/2018



Medibio Signs Agreement with Striiv to Accelerate Commercialisation

- Medibio's proprietary technology to be integrated into Striiv's mobile app that has 1m+ subscribers
- Striiv has corporate partnerships with UnitedHealth, Qualcomm Life, and Pfizer

Sydney, Australia and Minneapolis, MN – 22 January 2018: Medibio Limited (MEB or the Company) (ASX: MEB) (OTCQB: MDBIF), a mental health technology company that has pioneered the use of objective biometrics to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions, has signed a strategic partnership agreement with Striiv.

The strategic partnership is intended to allow Striiv to integrate Medibio's proprietary, personal mental health evaluation technology into its mobile app and assessment services, which has a user base of over 1 million subscribers. Because Striiv has wrist-wearable devices, this partnership provides the opportunity for Medibio's technology to be used for longer term patient monitoring and management. Medibio anticipates completing integration with Striiv in this fiscal year.

This partnership also reflects Striiv's deep commitment to the development of novel ways to improve wellness. In addition to the partnership with Medibio, Striiv has a history of successful collaborations with healthcare partners and corporate clients such as UnitedHealth Group Inc., Qualcomm Life, and Pfizer Inc. The UnitedHealthcare Motion program is an example of an innovative wellness program by UnitedHealthcare® in 40 states where members can earn \$1,000 or more each plan year by tracking and achieving goals. Powered by Qualcomm Life's 2net* technology, Striiv offers secure, medical-grade connectivity. Qualcomm Life worked with Striiv to integrate a customized, baseline device for the UnitedHealthcare Motion® program which created sustained engagement and real habit change.

Striiv also creates custom wearable solutions for healthcare partners, helping healthcare providers discover new ways to care for patients and empowering them to lead healthier lives. In addition, Striiv devices are available for purchase by individuals on its website and also through reseller agreements with Best Buy and Amazon that allow for a growing user base of its devices.

About Medibio Limited

Medibio (ASX: MEB) (OTCQB: MDBIF) is a mental health technology company that has pioneered the use of objective biometrics to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions. The company was founded in Australia, with offices located in Melbourne (Vic), and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au.

ASX Announcement





About Striiv Inc.

Striiv is a health technology services company spearheading the adoption of "at-home" universal screening and treatment programs for the pharmaceutical and insurance industry. By leveraging specialized sensors, Striiv is able to identify various health and behavioral risks. From precision medicine to early detection of various disease states, Striiv utilizes its advanced sensor biometric and behavioral validation to address the significant challenges in healthcare today, www.striiv.com

- ENDS -

Further Information:	Website: <u>www.medibio.com.au</u>
Medibio Shareholder Enquiries:	Australian Media Enquiries:
Stephanie Ottens	Peter Taylor
Investor Relations Director	NWR Communications
Medibio Limited	peter@nwrcommunications.com.au
stephanie.ottens@medibio.com.au	T: +61 (0) 412 036 231
T: +61 434 405 400	

^{*2}net is a trademark of Qualcomm Incorporated, registered in the United States and other countries.